Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi.
A 75-yr-old previously healthy woman presented with gross hematuria, European Cooperative Oncology Group 0, and an 11-cm renal mass with right atrial thrombus. The patient refused the sternotomy. She was offered two cycles of sunitinib maleate (Sutent) induction therapy to down-stage the thrombus and to reduce the extent of the surgery.
Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, QC, Canada. pierre.karakiewicz@umontreal.ca <pierre.karakiewicz@umontreal.ca>
Pierre I
PI
Karakiewicz
Nazareno
N
Suardi
Claudio
C
Jeldres
Pascale
P
Audet
Pierre
P
Ghosn
Jean-Jacques
JJ
Patard
Paul
P
Perrotte
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy*; D003328:Coronary Thrombosis / Q000000981:diagnostic imaging / Q000209:etiology / Q000517:prevention & control*; D003937:Diagnosis, Differential; D005260:Female; D006325:Heart Atria; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D020360:Neoadjuvant Therapy; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed; D014463:Ultrasonography
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib